Skip to content

Comparison between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention

Comparison between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention - SLIM 2 study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON51007
Enrollment
1174
Registered
2021-05-06
Start date
2022-09-08
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Coronary Syndrome Coronary Artery Disease Clogged coronary arteries

Interventions

Group 2 (intervention): DOAC continuation In group 2, all patients will continue to use their specific DOAC as usual. This means that no adjustments of DOAC use will be made before and after ICA or

Sponsors

Zuyderland
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: o Patients aged between 18-85 years using DOAC and undergoing elective ICA or PCI. o Written informed consent

Exclusion criteria

Exclusion criteria: - Patients initially presenting with Acute Coronary Syndrome (STEMI, NSTEMI, UA) - Patients <18 or >85 years old - Calculated CLCR <30 mL/min - Patients simultaneously participating in another clinical trial - History or condition associated with increased bleeding risk, as listed below: o Major surgical procedure within 30 days before the procedure o Pre-procedural expectation that exclusive radial access is infeasible, including cases with a previously documented inaccessible radial artery. o History of GI bleeding in the previous 6 months o History of intracranial, intraocular, spinal, or atraumatic intra-articular  bleeding o Chronic bleeding disorder o Known intracranial neoplasm, arteriovenous malformation, or aneurysm o Known anemia with last measured haemoglobin value <6 mmol/L [9.67 g/dL] o Current pregnancy or breast-feeding o Known significant liver disease (e.g., acute clinical hepatitis, chronic  active hepatitis, cirrhosis), or ALT >3 x the ULN

Design outcomes

Primary

MeasureTime frame
Primary endpoint In hospital major bleeding, BARC bleeding definition 3 or 5.

Secondary

MeasureTime frame
Secondary endpoints • 30 days follow-up - Major bleeding, BARC bleeding definition 3 or 5. - Major adverse cardiac and cerebrovascular events (MACCE): composite of death, myocardial infarction, revascularisation and stroke (haemorrhagic or ischemic) - NACE: the composite of MACE and major or minor bleeding. - Myocardial infarction - Stroke - Minor bleeding, BARC bleeding definition 1-2.

Countries

Czech Republic, Hungary, Netherlands

Contacts

Public ContactS Janssen

Zuyderland

sanne.janssen@zuyderland.nl088 – 459 9701

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Apr 17, 2026